This report provides all the information you require to better understand Aspen and its partnering interests and activities over the past seven years

Aspen Pharma, a global branded and generics pharmaceutical manufacturer, has found a place in the top 50 big pharma companies listed by Current Partnering.

Aspen Pharmacare specialises in the production of branded and generic pharmaceuticals and is currently the biggest pharmaceutical company in South Africa taking a 15% share of the total market.

GlaxoSmithKline, a big pharma company, is discussing pharma deals for the sale of its thrombosis drug brands Arixtra and Fraxiparine, along with a related French factory, to Aspen Pharmacare in a deal that could be worth some $1 billion.

A busy week for life science financings in an otherwise quiet week for dealmakers

Return to top 50 pharma list Summary Website: Aspen Headquarters:  Durban, South Africa Ticker Symbol: AZPN:NASDAQ GS SEC Link: Aspen Subsidiaries: Shelys Pharmaceuticals Top 50 Pharma ranking*: 47 *Ranking based on reported global pharma sales for year ending December 2013. Sales revenue (USD billions) [% change from 2010]: $1.7 R&D spend (USD millions): $1.3 Top-selling drugs (USD billions): N/A Partnering more »

Partnering gains momentum whilst M&A slows significantly

Aspen Pharmacare is set to acquire the drug making arm of Australia’s Sigma Pharmaceuticals for $804 million

Sigma Pharmaceuticals was playing its cards close to the vest last week when it denied a higher buyout offer from South Africa’s Aspen Pharmacare.

Sigma Pharmaceuticals denied Australian media reports that Aspen Pharmacare Holdings had boosted its buyout offer for the company to 65 cents per share, or $689 million; Aspen’s formal bid made last month was 55 cents per share.

Africa’s biggest drug maker Aspen Pharmacare announced in May that it was planning to acquire Sigma Pharmaceuticals in a takeover offer worth $589 million.

GSK has agreed to the sale of 28.2 million ordinary shares in Aspen Pharmacare Holdings

Aspen has entered into an agreement with Novartis in terms of which it will acquire the rights to Mono-Embolex

Iroko Pharmaceuticals signed a licensing agreement with Aspen Pharma for the exclusive rights to register and market ZORVOLEX (diclofenac) capsules in Australia and New Zealand.

GlaxoSmithKline will acquire a stake in the Japanese subsidiary of Aspen Pharmacare Holdings as part of an alliance to boost commercial operations in the Asian country.

Mylan announces the acquistion of the U.S. commercialization, marketing and intellectual property rights of Arixtra.

Vivus is the subject of a buyout rumor for $640 million.

Aspen has entered big pharma deals with Merck and Co for an asset purchase agreement in which Aspen will by Merck’s API business.

A pharma partners contract worth $667 million was jointly awarded by South Africa to three big names in the pharma world, Aspen Pharmacare, Abbott Laboratories and Adcock Ingram, to supply life-prolonging HIV medicine to 12 international and domestic firms, to deal with its biggest health problem.

Drug maker Cipla has entered in a pharma partners collaboartion with South Africa’s Aspen Pharmacare, a big pharma company to cater to the Australian market.

GlaxoSmithKline and Aspen Pharmacare, both big pharma companies have inked new pharma deals wherein, GSK will sell 25 older brands marketed in Australia to South Africa’s Aspen Pharmacare  for 172 million pounds ($270 million).